Gallen guidelines, the panel recommended PMRT in cases of one to three positive nodes with a triple-negative histology, but it was divided on whether women should receive PMRT in cancers that are HER2-positive and/or ER-positive with one to three involved lymph nodes [27]. Here, ESR1 is linked to cancer.